How an mRNA-encoded antibody platform could accelerate therapies to clinic Therapeutic antibody production is traditionally complex and costly, which drives up treatment prices. However, encoding antibodies with mRNA offers a potential solution to many of these challenges, making the process…
In this talk, we dive into the critical quality attributes (CQAs) of mRNA and lipid nanoparticles (LNPs) that directly impact drug efficacy and safety. You’ll gain insights into essential and cutting-edge analytical techniques and nanopore sequencing, mass spectrometry, and laser-induced…
New Leadership Reflects Commitment to Advancing mRNA Technologies and Operational Excellence, Helping Drug Developers Deliver Innovative Therapies Faster. COLCHESTER, Vt., October 31, 2024 /BUSINESS WIRE/ — Vernal Biosciences Inc., a leader in mRNA and lipid nanoparticle (LNP) development, manufacturing, and…
In this video series exploring biotech innovation, Christian Cobaugh, founder and CEO of Vernal, discusses the critical role of analytical services in the success of mRNA and lipid nanoparticles (LNPs) therapeutics. Interviewed by Kristyn Cook, Executive Director of Marketing, he…
COLCHESTER, Vt., October 9, 2024 — Vernal Biosciences, a leader in mRNA and lipid nanoparticle (LNP) manufacturing, announces that its analytical and quality control (QC) services for plasmid DNA, mRNA, and LNPs are now commercially available as part of its…
In the fast-paced world of early-stage mRNA product and process development, it’s not just about ideas and innovation; it’s about how quickly and accurately you can measure your outcomes. Since those precious outcomes depend on the confidence you have in…
In the latest episode of the Speaking of Mol Bio Podcast, hosts Steve Lewis and Dr. Christian Cobaugh, CEO of Vernal Biosciences, delve into the fascinating world of mRNA technology. The COVID pandemic has brought mRNA into the spotlight, showcasing…
Podcast Abstract: In the latest episode of the Absolute Gene-ius Podcast, hosts Christina Bouwens and Dr. Christian Cobaugh, CEO of Vernal Biosciences, dive into the evolving landscape of mRNA technology and democratizing mRNA technology. With a mission to enhance access…
Authored by: Christian Cobaugh, Grant Henderson and Khaled Yamout The FDA’s new guidance clarifies eligible Platform Technologies must adhere to the statutory definition and require consistent CMC processes. Applicants can recycle features across products, while those lacking assets can leverage CDMOs like…
In the fast-paced world of biopharmaceuticals, choosing the right contract development and manufacturing organization (CDMO) is crucial to the success of your drug development program. At Vernal Biosciences, we pride ourselves on being a US-based CDMO that produces all products domestically. Here…
If you are not on our mailing list, email us at [email protected]! You can click “contact us” in the upper right hand corner of this webpage to inquire about our Cas9 Demo batch, and HERE to watch the video of…
Experience the incredible insights Vernal has to offer regarding its cutting-edge capping technology and the exceptional quality of our mRNA. We will be showcasing this groundbreaking information through three posters at the International mRNA Health Conference in Berlin. You can…